Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis
Journal of Neuromuscular Diseases · 2026-11 · 13 (6) · 1406-1412
DOI: 10.1177/22143602261442297 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 29.04.2026. Verfasst von Lars K Markvardsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Immunoglobulins, Immunologic Factors. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danish Regions.
Abstract (Originalsprache)
Background
In a previous study we demonstrated that standardized tapering off subcutaneous immunoglobulin (SCIG) is a safe way to identify remission in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). However, clinical characteristics and dosage of SCIG in patients in remission are unknown.
Methods
In the present study, we aimed to identify characteristics of patients in remission during tapering off SCIG. Participants received a stable SCIG dosage and followed a standardized tapering off regimen providing 90%, 75%, 50%, 25% and 0% of the initial dose, every 12 th week, pending no deterioration occurred. All patients were followed for 164 weeks after inclusion and were evaluated with disability scores, quality of life score (EQ-5D-5L), blood samples and clinical examination.
Results
Receiving a dosage of SCIG >25 g/week predicts a higher risk of relapse, OR 6.3 (95CI 1.8-20.2)(p = 0.004), but not when considering body weight (SCIG >0.3 g/kg/week), OR 3.3 (95CI 1.0-9.7)(p = 0.05). Moreover, a higher level of serum NfL OR 8.2 (95CI 1.1-93.3)(p = 0.04) predicts relapse. Low scores on EQ-5D-5L at baseline predicted increased risk of relapse. Serum calprotectin was similar in patients with relapse and in remission. Evaluating measurements from baseline, final visit and the last visit before final visit (LVBF), we found that deterioration in clinical performance could not be predicted at LVBF based on any of the tests performed.
Conclusion
Patients experiencing a relapse of CIDP during tapering off SCIG seem to receive a total higher dosage of immunoglobulin and had a higher sNfL prior to tapering off compared to patients without a relapse.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Neurology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Neurology, Esbjerg Hospital, Esbjerg, Denmark.
- Department of Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
- Department of Neurology, Odense University Hospital, Odense, Denmark.
ORCID-Profile: Lars K Markvardsen, Helga Haahr-Lillevang
Förderung
- Danish Regions
Zitieren
APA
Markvardsen, L. K., Haahr-Lillevang, H., Sejbæk, T., Parkner, T., Sindrup, S. H., Jakobsen, J., & Andersen, H. (2026). Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis. Journal of Neuromuscular Diseases, 13(6), 1406-1412. https://doi.org/10.1177/22143602261442297
Vancouver
Markvardsen LK, Haahr-Lillevang H, Sejbæk T, Parkner T, Sindrup SH, Jakobsen J, et al. Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis. Journal of Neuromuscular Diseases. 2026;13(6):1406-1412. doi:10.1177/22143602261442297
BibTeX
@article{Markvardsen2026,
author = {Markvardsen, Lars K and Haahr-Lillevang, Helga and Sejbæk, Tobias and Parkner, Tina and Sindrup, Søren H and Jakobsen, Johannes and Andersen, Henning},
title = {Predictors of relapses in patients with chronic inflammatory demyelinating polyneuropathy receiving subcutaneous immunoglobulin therapy – a post-hoc analysis},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
volume = {13},
number = {6},
pages = {1406--1412},
doi = {10.1177/22143602261442297}
}
EUVIMED